Literature DB >> 16533960

Treatment of glioblastoma multiforme: a new standard.

John W Henson1.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16533960     DOI： 10.1001/archneur.63.3.337

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  12 in total

1.  Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain.

Authors:  Gabriel Charest; Léon Sanche; David Fortin; David Mathieu; Benoit Paquette
Journal:  J Neurooncol       Date:  2013-09-13       Impact factor: 4.130

Review 2.  Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.

Authors:  Dewen Yang
Journal:  Neurooncol Pract       Date:  2015-07-12

3.  Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.

Authors:  Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Daniel Antunes Moreno; Veridiana Kill Suazo; Mayara Missono Fujinami; Rosane de Paula Gomes Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

4.  Mahanine, a novel mitochondrial complex-III inhibitor induces G0/G1 arrest through redox alteration-mediated DNA damage response and regresses glioblastoma multiforme.

Authors:  Kaushik Bhattacharya; Arup K Bag; Rakshamani Tripathi; Suman K Samanta; Bikas C Pal; Chandrima Shaha; Chitra Mandal
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

5.  Function of neuronal nitric oxide synthase enzyme in temozolomide-induced damage of astrocytic tumor cells.

Authors:  Fernando Francisco Borges Resende; Simoneide Souza Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Oncol Lett       Date:  2018-02-01       Impact factor: 2.967

6.  Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Authors:  David M Peereboom; Dale R Shepard; Manmeet S Ahluwalia; Cathy J Brewer; Neeraj Agarwal; Glen H J Stevens; John H Suh; Steven A Toms; Michael A Vogelbaum; Robert J Weil; Paul Elson; Gene H Barnett
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

7.  Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents.

Authors:  Atsushi Kambe; Genzo Iguchi; Yuseok Moon; Hideki Kamitani; Takashi Watanabe; Thomas E Eling
Journal:  Biochim Biophys Acta       Date:  2008-02-20

8.  The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells.

Authors:  Atsushi Kambe; Hiroki Yoshioka; Hideki Kamitani; Takashi Watanabe; Seung Joon Baek; Thomas E Eling
Journal:  Cancer Prev Res (Phila)       Date:  2009-11-24

9.  Mitochondrial KATP Channels Control Glioma Radioresistance by Regulating ROS-Induced ERK Activation.

Authors:  Lianyan Huang; Boxing Li; Shihao Tang; Hongbo Guo; Wenjun Li; Xiaozhou Huang; Wenjuan Yan; Fei Zou
Journal:  Mol Neurobiol       Date:  2014-09-24       Impact factor: 5.590

10.  Concurrent Chemotherapy of Malignant Glioma in Rats by Using Multidrug-Loaded Biodegradable Nanofibrous Membranes.

Authors:  Yuan-Yun Tseng; Yin-Chen Huang; Tao-Chieh Yang; Shun-Tai Yang; Shou-Cheng Liu; Tzu-Min Chang; Yi-Chuan Kau; Shih-Jung Liu
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.